Megace ES Articles
Par Pharma challenges FDA authority on off-label promotion
23 October 2011
Stock Commentary - New York week to March 30, 2009
2 April 2009
Pharma Resources claims victory in B-MS lawsuit
17 July 2001
Aromasin cuts mortality in breast cancer
20 May 1999
Zeneca Files New Data With MCA For Arimidex
6 January 1997
Ciba Launches Femara And Diovan In The UK
2 December 1996
Record Sales For Barr Laboratories
9 September 1996
First Approval Of Ciba's Femara In France
5 August 1996
Barr Labs and generic version of B-MS' Megace
4 December 1995
Zeneca's Arimidex Launched In First Market
25 September 1995
Megace Linked To Adrenal Insufficiency?
21 August 1995
Comparative Arimidex Data From ASCO
29 May 1995
CANADIAN FIRMS GIVING UP PATENTS
17 January 1994
BM-S IN C$1 MILL SETTLEMENT
20 December 1993
NEW FORMULATION OF B-MS' MEGACE
27 September 1993
ANABOLIC STEROIDS FOR AIDS WASTING?
21 June 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
MEGACE BACKED FOR AIDS WEIGHT LOSS
8 March 1993
SUPPORTIVE CARE DRUGS IN CANCER: ASCO DATA
25 May 1992
Showing 1-23 of 23 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
